Heat Biologics

Heat Biologics Inc. is a US biotechnology company focused on the field of cancer immunotherapy. This company's cancer vaccine is called ImPACT, short for Immune Pan-Antigen Cytotoxic Therapy. ImPACT is in Phase II clinical trials and is being tested in NSCLC and bladder cancer. It is based in Morrisville, North Carolina.

For other uses, see Biological thermodynamics.
Heat Biologics
Public
Traded asNASDAQ: HTBX
IndustryBiotechnology
Founded2008
HeadquartersDurham, NC
Key people
Jeffrey Wolf
(Chairman and CEO)
ProductsHS-110, HS-X20
Websitewww.heatbio.com

Impact

ImPACT is a proposed cancer vaccine based on live, genetically-modified, irradiated human cells which secrete a broad spectrum of cancer-associated antigens as well as an immune adjuvant called gp96. Potential advantages of this product are use as an 'allogeneic', that is, 'off-the-shelf' immunotherapy, and its applicability to a wide range of cancers. It is in phase II trials.

ImPACT originated in the late 1990s in work done at the University of Miami which showed that gp96, a heat shock protein resident in the endoplasmic reticulum could be made immunogenic if part of gp96 was replaced with the Fc portion of an IgG1 antibody to engineer a secretory form of gp96. In vivo gp96-Ig generated a strong CD8+ T cell response[1]

ComPACT

ComPACT is a combination of a pan-antigen T cell priming vaccine and a T cell co-stimulator.[2]

Other potential products

HS-410

HS-410, also called vesigenurtacel-L, is currently in Phase II in Non-Muscle-Invasive Bladder Cancer (NMIBC), in combination with BCG.[3] In Feb 2016 patient enrollment was paused (for lack of BCG).[4]

HS-110

HS-110, also called viagenpumatucel-L, is in Phase II in NSCLC, in combination with cyclophosphamide. Another Phase I study is combining HS 110 with nivolumab and other checkpoint inhibitors.

COVID-19 Vaccine

The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020 using their gp96 platform which activates the human immune system to combat infectious diseases with the potential of generating long-term immune responses.

Heat Biologics stock

Heat Biologics stock has been traded on the NASDAQ under ticker symbol HTBX since 24 July 2013.[5]

Main people

Heat Biologics' Chairman and CEO is Jeffrey Wolf, a serial Life Sciences entrepreneur who founded the company in 2008. Its Chief Scientific Officer is Dr. Jeff Hutchins.

gollark: It is beginning to document the incident report logs, though.
gollark: Hey, the blasphemy counter works!
gollark: Hello SolarFlame5!
gollark: Yes.
gollark: That is a texture pack and a half.

References
  1. Yamazaki K; Nguyen T; Podack ER. (November 15, 1999). "Cutting edge: tumor secreted heat shock-fusion protein elicits CD8 cells for rejection". Nucleic Acids Research. 163 (10): 5178–82. doi:10.1093/nar/gkq055. PMC 2887946. PMID 10553037.
  2. "T Cell therapies 'Heat' up as biotech looks to third public offering". biopharma-reporter.com.
  3. "A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
  4. "Heat Biologics stops enrolment in trial arm testing HS-410 as a bladder cancer monotherapy". biopharma-reporter.com.
  5. "Heat Biologics, Inc. Announces Closing of Initial Public Offering of 2,500,000 Shares of Common Stock". Heatbio.com. July 29, 2013. Retrieved 1 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.